Brief: Beyondspring Announces Three Presentations Highlighting Positive Clinical Outcome Data From The Phase 3 Program Of Plinabulin
07/06/2021 12:13
June 7 (Reuters) - Beyondspring Inc BYSI.O :
* BEYONDSPRING ANNOUNCES THREE PRESENTATIONS HIGHLIGHTING
POSITIVE
CLINICAL OUTCOME DATA FROM THE PHASE 3 PROGRAM OF PLINABULIN IN
COMBINATION WITH PEGFILGRASTIM FOR THE PREVENTION OF
CHEMOTHERAPY-INDUCED NEUTROPENIA AT THE AMERICAN SOCIETY OF
CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
Source text for Eikon: ID:nGNX1KFxYs
Further company coverage: BYSI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Beyondspring
See all newsBrief: Beyondspring Inc Entered Into Open Market Sale Agreement Under Which Co May Offer And Sell Up To 9.2 Million Ordinary Shares
Brief: Beyondspring Announces FDA Fast Track Designation For Plinabulin In Post-Ici Non-Squamous Nsclc And Strategic Transaction To Advance Global Phase 3 Dublin-4 Trial Toward Planned Interim Analysis
NASDAQ RESUMED AT 12:26 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:21 PM
Brief: Beyondspring Announces Leadership Transition To Deliver Focused Execution On Its Confirmatory Dublin-4 Program And Long-Term Value